An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Belite Bio, Inc. (BLTE) will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference and conduct a virtual presentation on February 14, 2024. The company focuses on developing therapeutics for degenerative retinal diseases with unmet medical needs. The webcast of the presentation can be accessed on the investor relations section of the Belite Bio website. The replay will be available for 90 days.
Positive
None.
Negative
None.
SAN DIEGO, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate at the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13-14 and conduct a virtual presentation. The virtual presentation will take place on Wednesday, February 14, 2024, at 12:40 pm ET.
A webcast of the presentation can be accessed under the "Events" tab on the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events. The replay will be archived for 90 days following the presentation date.
About Belite Bio Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt Disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook, or visit us at www.belitebio.com.
Media and Investor Relations Contact: Jennifer Wu ir@belitebio.com
Julie Fallon belite@argotpartners.com
Belite Bio will participate in the conference on February 13-14, 2024.
Belite Bio focuses on advancing novel therapeutics targeting degenerative retinal diseases with unmet medical needs.
The webcast can be accessed under the 'Events' tab on the investor relations section of the Belite Bio website.
The replay will be archived for 90 days following the presentation date.
belite bio inc is a san diego based clinical stage biopharmaceutical drug development company targeting untreatable age-related metabolic diseases, including macular degeneration, liver disease and diabetes. developed from our anti-rbp4 technology platform, our lead candidate, lbs-008, is currently in a phase i clinical trial for dry age-related macular degeneration and its juvenile form, stargardt disease. lbs-008 has received orphan drug status in the us and europe, as well as rare pediatric disease status in the us.